Protherics to take over Roche's digitalis antidote business
UK-based biopharmaceutical firm Protherics says that it has received marketing rights to Digitalis Antidote, a treatment for digitalis poisoning, from Swiss drug major Roche. The company added that the deal is part of an overall agreement between the two firms that will seek to replace the agent with Protherics' own DigiFab product from early 2007.
Protherics said that it would work with Roche to facilitate the smooth market transition from its drug, which is currently approved in France, Germany and Switzerland, to DigiFab which holds US Food and Drug administration approval for the treatment of digoxin toxicity or overdose. The Brentwood-headquartered company said that European marketing authorization for DigiFab would be sought, with the aim of making it available early next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze